Several COVID-19 vaccines, some more efficacious than others, are now available and
deployed, including multiple mRNA-and viral vector-based vaccines. With the focus on …

The novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2),
was identified in December of 2019 and is responsible for millions of infections and deaths …

With the success of messenger RNA (mRNA) vaccines against coronavirus disease 2019,
strategies can now focus on improving vaccine potency, breadth, and stability. We designed …

SARS-CoV-2 infection has emerged as a serious global pandemic. Because of the high
transmissibility of the virus and the high rate of morbidity and mortality associated with …

To successfully protect against pathogen infection, a vaccine must elicit efficient adaptive
immunity, including B and T cell responses. While B cell responses are key, as they can …

Messenger RNA (mRNA) vaccines are promising alternatives to conventional vaccines in
many aspects. We previously developed a lipopolyplex (LPP)‐based mRNA vaccine …

Emergency use authorization of COVID vaccines has brought hope to mitigate pandemic of
coronavirus disease 2019 (COVID-19). However, there remains a need for additional …

Establishment of an mRNA vaccine platform in low-and middle-income countries (LMICs) is
important to enhance vaccine accessibility and ensure future pandemic preparedness. Here …

More than a year after emergence of the SARS-CoV-2 pandemic, multiple first-generation
vaccines are approved and available for vaccination. Still, many challenges remain. The …

Combining optimized spike (S) protein-encoding mRNA vaccines to target multiple SARS-
CoV-2 variants could improve control of the COVID-19 pandemic. We compare monovalent …